Black Diamond Therapeutics Q4 2023 Earnings Report

Black Diamond Therapeutics EPS Results

• Actual EPS: -$0.34
• Consensus EPS: -$0.47
• Beat/Miss: Beat by +$0.13
• One Year Ago EPS: N/A

Black Diamond Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Black Diamond Therapeutics Announcement Details

• Quarter: Q4 2023
• Date: 3/12/2024
• Time: N/A
• Conference Call Date: Tuesday, March 12, 2024
• Conference Call Time: 8:00AM ET

Black Diamond Therapeutics (NASDAQ:BDTX) is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations. Black Diamond’s approach seeks to overcome resistance mechanisms that often limit the efficacy of existing therapies by focusing on mutation-specific vulnerabilities. Early-stage clinical trials for BDTX-189 are evaluating safety, pharmacokinetics, and anti-tumor activity in patients whose tumors harbor HER2 alterations.

Founded in 2019 and listed on the Nasdaq under the ticker BDTX, Black Diamond Therapeutics combines scientific expertise with experience drawn from leading biopharmaceutical organizations. The company collaborates with academic centers and research institutions to advance its pipeline and is committed to delivering next-generation precision medicines to oncology patients worldwide.